Artemether-Lumefantrine (ACT Combi Kit) Dosing Regimen
For adults and children >35 kg with uncomplicated P. falciparum malaria, administer artemether-lumefantrine as 4 tablets (80 mg artemether/480 mg lumefantrine) given at 0,8,24,36,48, and 60 hours (total of 24 tablets over 60 hours), taken with fatty food or drink. 1
Weight-Based Dosing Algorithm
Adults and Children ≥35 kg
- 4 tablets per dose (each tablet = 20 mg artemether + 120 mg lumefantrine)
- Day 1: 4 tablets at hour 0, then 4 tablets at hour 8
- Day 2: 4 tablets at hour 24 (morning), then 4 tablets at hour 36 (evening)
- Day 3: 4 tablets at hour 48 (morning), then 4 tablets at hour 60 (evening)
- Total: 24 tablets over 72 hours 1, 2
Pediatric Dosing (Weight-Based)
The dosing is strictly weight-based for children, not age-based, as middle age/weight bands have higher rates of dosing errors 3:
- 5 to <15 kg: 1 tablet per dose (6 doses over 60 hours)
- 15 to <25 kg: 2 tablets per dose (12 tablets total)
- 25 to <35 kg: 3 tablets per dose (18 tablets total)
- ≥35 kg: 4 tablets per dose (24 tablets total) 1, 2
Critical Administration Requirements
Food is mandatory: Artemether-lumefantrine must be taken with a fatty meal or drink to ensure adequate absorption. This is non-negotiable as lumefantrine absorption is highly fat-dependent 1, 2. Without fat, bioavailability drops significantly, risking treatment failure.
Supervised dosing: Day 7 lumefantrine concentrations are 44% lower with unsupervised treatment 4. The first dose should ideally be directly observed, and adherence counseling is essential.
High-Risk Populations Requiring Close Monitoring
Three groups have increased treatment failure risk and warrant enhanced surveillance 4:
- Very young children (<3 years), especially those underweight-for-age who have 23% lower drug concentrations than adequately nourished children and 53% lower than adults
- Patients with high parasitemia (>135,000/μL or >4-5%)
- Patients in areas with emerging artemisinin resistance or very low transmission intensity
For these populations, consider checking Day 7 lumefantrine levels if available; therapeutic threshold is ≥200 ng/mL for >98% cure rates 4.
Important Caveats and Drug Interactions
QT prolongation risk: Avoid in patients with:
- Known QT prolongation or risk factors
- Concomitant medications that prolong QT (macrolides, antiarrhythmics, certain antidepressants)
- Electrolyte abnormalities 1, 2
Contraindicated combinations 2:
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) reduce artemether, DHA, and lumefantrine exposure by 68-89%
- CYP2D6 substrates that prolong QT (flecainide, tricyclic antidepressants)
Pregnancy: Can be used in all trimesters per WHO and CDC guidelines 1
Pharmacokinetic Rationale
The six-dose regimen achieves 87-97% corrected cure rates versus 74-87% with the older four-dose regimen 5. Artemether has rapid parasite clearance (half-life ~2 hours) while lumefantrine provides sustained coverage (half-life 3-6 days) 2. The combination prevents resistance development through complementary mechanisms of action 1.
Dosing on mg/kg basis in children (≥5 to <35 kg) produces comparable systemic exposure to adults when following the weight-based bands 2, 6.
Monitoring and Follow-Up
- Assess clinical response at 3 days; if no improvement, consider alternative diagnosis or treatment failure
- Day 7 follow-up recommended, especially for high-risk groups
- Monitor for post-artesunate delayed hemolysis (PADH) in severe malaria cases transitioned to oral therapy 1